Investor Presentation
14
Investor presentation
First six months of 2022
R&D milestones for 2022
Project
Diabetes care
FDC Sema OW GIP
Q2 2022
Phase 1 results
Obesity care
CagriSema T2DM
RybelsusⓇ
Icodec
Higher doses inj. sema
Oral FDC sema/SGLT2i
SELECT CVOT
CagriSema
Oral amycretin
Rare disease
Other serious
chronic diseases
CN submission
Novo NordiskⓇ
Clinical milestones¹
Regulatory milestones¹
Q3 2022
Q4 2022
Phase 2 results
Phase 3a results
Phase 2 initiation
Phase 1 initiation
Interim analysis
Phase 1 initiation
LA-GDF15
Phase 1 results
Sogroya® (somapacitan)
Mim8
US/EU/JP submission (GHD)
Phase 3 initiation
Phase 3 treatment²
Concizumab
US/JP submission (HwI)
Phase 3a results (HA/HB)
NDec (Sickle cell disease)
NNC6019 (ATTR-CM)
Phase 2 initiation
Phase 2 initiation
1 Expected to be published in the given quarter or in the subsequent quarterly company announcement. 2 First patient first visit in Q4 2021, which is solely for baselining purposes
GHD: Growth Hormone Deficiency; sema: semaglutide; HwI: Haemophilia with inhibitors; ATTR-CM: Transthyretin Amyloid Cardiomyopathy; CVOT: Cardiovascular Outcomes Trial, FDC: Fixed dose combination; NDec was previously known as Eclipse and NNC6019
was previously known as PRX004View entire presentation